Costs and of treating Gleason score 9 and 10 prostate cancer vary widely based on need for adjuvant therapy: A critical assessment into the long-term cost implications of additional treatment modalities.
Aaron A. Laviana(Vanderbilt University Medical Center), Amar U. Kishan(University of California, Los Angeles), D. Jeffrey Demanes(University of California, Los Angeles), Michael L. Steinberg(University of California, Los Angeles), Robert E. Reiter(University of California, Los Angeles), Christopher S. Saigal(University of California, Los Angeles), Christopher King(National Institute of Neurological Disorders and Stroke), Matthew J. Resnick(Vanderbilt University Medical Center), Eric M. Horwitz(Fox Chase Cancer Center)
Cited by 0
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
|Journal of Clinical Oncology|2008|691
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656